{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:37:22Z","timestamp":1768545442426,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NRIIS","award":["project number 4790478"],"award-info":[{"award-number":["project number 4790478"]}]},{"name":"ITB research grant","award":["No. 959\/IT1.B07.1\/TA.00\/2024"],"award-info":[{"award-number":["No. 959\/IT1.B07.1\/TA.00\/2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00680-7","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:30:35Z","timestamp":1761319835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro and in silico evaluation of synthesized 4-Anilinoquinazoline derivatives as potential anticancer agents"],"prefix":"10.1007","volume":"39","author":[{"given":"Yusuf Eka","family":"Maulana","sequence":"first","affiliation":[]},{"given":"Ade","family":"Danova","sequence":"additional","affiliation":[]},{"given":"Chanat","family":"Aonbangkhen","sequence":"additional","affiliation":[]},{"given":"Jaruwan","family":"Chatwichien","sequence":"additional","affiliation":[]},{"given":"Sutthida","family":"Wongsuwan","sequence":"additional","affiliation":[]},{"given":"Elvira","family":"Hermawati","sequence":"additional","affiliation":[]},{"given":"Warinthorn","family":"Chavasiri","sequence":"additional","affiliation":[]},{"given":"Anita","family":"Alni","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"680_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"680_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"680_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J et al (2022) Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 77:1598\u20131606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J Hepatol"},{"key":"680_CR4","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.neuron.2022.07.012","volume":"110","author":"M Zeineldin","year":"2022","unstructured":"Zeineldin M, Patel AG, Dyer MA (2022) Neuroblastoma: When differentiation goes awry. Neuron 110:2916\u20132928. https:\/\/doi.org\/10.1016\/j.neuron.2022.07.012","journal-title":"Neuron"},{"key":"680_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41588-023-01395-x","volume":"55","author":"G Gundem","year":"2023","unstructured":"Gundem G, Levine MF, Roberts SS et al (2023) Clonal evolution during metastatic spread in high-risk neuroblastoma. Nat Genet 55:1022\u20131033. https:\/\/doi.org\/10.1038\/s41588-023-01395-x","journal-title":"Nat Genet"},{"key":"680_CR6","doi-asserted-by":"publisher","first-page":"101393","DOI":"10.1016\/j.tranon.2022.101393","volume":"19","author":"WJ Gong","year":"2022","unstructured":"Gong WJ, Cao P, Zhang QL et al (2022) Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling. Transl Oncol 19:101393. https:\/\/doi.org\/10.1016\/j.tranon.2022.101393","journal-title":"Transl Oncol"},{"key":"680_CR7","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/c8dt00838h","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun R, Moussa YE, Wheate NJ (2018) The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans 47:6645\u20136653. https:\/\/doi.org\/10.1039\/c8dt00838h","journal-title":"Dalton Trans"},{"key":"680_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1039\/d2md00023g","volume":"13","author":"AR Dwivedi","year":"2022","unstructured":"Dwivedi AR, Kumar V, Prashar V et al (2022) Morpholine substituted quinazoline derivatives as anticancer agents against MCF-7, A549 and SHSY-5Y cancer cell lines and mechanistic studies. RSC Med Chem 13:599\u2013609. https:\/\/doi.org\/10.1039\/d2md00023g","journal-title":"RSC Med Chem"},{"key":"680_CR9","doi-asserted-by":"publisher","first-page":"106037","DOI":"10.1016\/j.phrs.2021.106037","volume":"175","author":"R Roskoski","year":"2022","unstructured":"Roskoski R (2022) Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacol Res 175:106037. https:\/\/doi.org\/10.1016\/j.phrs.2021.106037","journal-title":"Pharmacol Res"},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071878","volume":"12","author":"S Znati","year":"2020","unstructured":"Znati S, Carter R, Vasquez M et al (2020) Radiosensitisation of hepatocellular carcinoma cells by vandetanib. Cancers 12:1\u201317. https:\/\/doi.org\/10.3390\/cancers12071878","journal-title":"Cancers"},{"key":"680_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canlet.2019.05.011","volume":"457","author":"H Li","year":"2019","unstructured":"Li H, Yu Y, Zhao Y et al (2019) Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett 457:129\u2013141. https:\/\/doi.org\/10.1016\/j.canlet.2019.05.011","journal-title":"Cancer Lett"},{"key":"680_CR12","first-page":"5842","volume":"2","author":"S Srinivas","year":"2013","unstructured":"Srinivas S, Aparna V (2013) Design, synthesis, biological evaluation and molecular docking studies of novel quinazoline derivatives as GSK-3\u03b2 inhibitors. World J Pharm Pharm Sci 2:5842\u20135851","journal-title":"World J Pharm Pharm Sci"},{"key":"680_CR13","unstructured":"Vishwakarma RA, Bharate SB, Bhushan S, et al (2019) 6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors. US Patent, 10202374B2"},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.bmc.2016.02.017","volume":"24","author":"Y Tu","year":"2016","unstructured":"Tu Y, Ouyang Y, Xu S et al (2016) Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. Bioorg Med Chem 24:1495\u20131503. https:\/\/doi.org\/10.1016\/j.bmc.2016.02.017","journal-title":"Bioorg Med Chem"},{"key":"680_CR15","doi-asserted-by":"publisher","first-page":"14250","DOI":"10.1038\/s41598-022-18460-w","volume":"12","author":"K Supabowornsathit","year":"2022","unstructured":"Supabowornsathit K, Faikhruea K, Ditmangklo B et al (2022) Dicationic styryl dyes for colorimetric and fluorescent detection of nucleic acids. Sci Rep 12:14250. https:\/\/doi.org\/10.1038\/s41598-022-18460-w","journal-title":"Sci Rep"},{"key":"680_CR16","doi-asserted-by":"publisher","first-page":"7258","DOI":"10.1021\/jm901202b","volume":"52","author":"M Tercel","year":"2009","unstructured":"Tercel M, Atwell GJ, Yang S et al (2009) Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents. J Med Chem 52:7258\u20137272. https:\/\/doi.org\/10.1021\/jm901202b","journal-title":"J Med Chem"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s12885-015-1387-6","volume":"15","author":"F Meng","year":"2015","unstructured":"Meng F, Bhupathi D, Sun JD et al (2015) Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer 15:422. https:\/\/doi.org\/10.1186\/s12885-015-1387-6","journal-title":"BMC Cancer"},{"key":"680_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-20-3555","volume":"27","author":"A Estrada-Bernal","year":"2021","unstructured":"Estrada-Bernal A, Le AT, Doak AE et al (2021) Tarloxotinib is a hypoxia-activated Pan-HER kinase inhibitor active against a broad range of HER-family oncogenes. Clin Cancer Res 27:1463\u20131475. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3555","journal-title":"Clin Cancer Res"},{"key":"680_CR19","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.bmc.2010.11.054","volume":"19","author":"YM McNamara","year":"2011","unstructured":"McNamara YM, Cloonan SM, Knox AJS et al (2011) Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents. Bioorg Med Chem 19:1328\u20131348. https:\/\/doi.org\/10.1016\/j.bmc.2010.11.054","journal-title":"Bioorg Med Chem"},{"key":"680_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejmech.2015.08.026","volume":"102","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yang Y, Zhou H et al (2015) Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. Eur J Med Chem 102:445\u2013463. https:\/\/doi.org\/10.1016\/j.ejmech.2015.08.026","journal-title":"Eur J Med Chem"},{"key":"680_CR21","doi-asserted-by":"publisher","first-page":"103790","DOI":"10.1016\/j.bioorg.2020.103790","volume":"99","author":"D Das","year":"2020","unstructured":"Das D, Xie L, Wang J et al (2020) In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR\/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Bioorg Chem 99:103790. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103790","journal-title":"Bioorg Chem"},{"key":"680_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bmcl.2018.12.056","volume":"29","author":"D Das","year":"2019","unstructured":"Das D, Xie L, Wang J et al (2019) Discovery of new quinazoline derivatives as irreversible dual EGFR\/HER2 inhibitors and their anticancer activities \u2013 Part 1. Bioorg Med Chem Lett 29:591\u2013596. https:\/\/doi.org\/10.1016\/j.bmcl.2018.12.056","journal-title":"Bioorg Med Chem Lett"},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"113701","DOI":"10.1016\/j.phytochem.2023.113701","volume":"211","author":"ER Sukandar","year":"2023","unstructured":"Sukandar ER, Kaennakam S, Wongsuwan S et al (2023) Schomburginones A-J, geranylated benzophenones from the leaves of garcinia schomburgkiana and their cytotoxic and anti-inflammatory activities. Phytochemistry 211:113701. https:\/\/doi.org\/10.1016\/j.phytochem.2023.113701","journal-title":"Phytochemistry"},{"key":"680_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/ph16081162","volume":"16","author":"G Shabir","year":"2023","unstructured":"Shabir G, Saeed A, Zahid W et al (2023) Chemistry and pharmacology of fluorinated drugs approved by the FDA (2016\u20132022). Pharmaceuticals 16:1162. https:\/\/doi.org\/10.3390\/ph16081162","journal-title":"Pharmaceuticals"},{"key":"680_CR25","doi-asserted-by":"publisher","first-page":"107578","DOI":"10.1016\/j.cclet.2022.06.001","volume":"34","author":"J He","year":"2023","unstructured":"He J, Li Z, Dhawan G et al (2023) Fluorine-containing drugs approved by the FDA in 2021. Chin Chem Lett 34:107578. https:\/\/doi.org\/10.1016\/j.cclet.2022.06.001","journal-title":"Chin Chem Lett"},{"key":"680_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/ph17030281","volume":"17","author":"E Henary","year":"2024","unstructured":"Henary E, Casa S, Dost TL et al (2024) The role of small molecules containing fluorine atoms in medicine and imaging applications. Pharmaceuticals 17:281. https:\/\/doi.org\/10.3390\/ph17030281","journal-title":"Pharmaceuticals"},{"key":"680_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422\u2013439. https:\/\/doi.org\/10.1016\/j.tips.2015.04.005","journal-title":"Trends Pharmacol Sci"},{"key":"680_CR28","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"680_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski CA (2004) Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337\u2013341. https:\/\/doi.org\/10.1016\/j.ddtec.2004.11.007","journal-title":"Drug Discov Today Technol"},{"key":"680_CR30","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1021\/jm000942e","volume":"43","author":"P Ertl","year":"2000","unstructured":"Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714\u20133717. https:\/\/doi.org\/10.1021\/jm000942e","journal-title":"J Med Chem"},{"key":"680_CR31","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1007\/s42250-024-01093-z","volume":"7","author":"ZB Sar\u0131","year":"2024","unstructured":"Sar\u0131 ZB, Sar\u0131 ME, Toruno\u011flu EI et al (2024) Bioactive compounds of plantago arenaria and their effects on SH-SY5Y cells: Phenolic content and docking analysis. Chem Afr 7:4741\u20134755. https:\/\/doi.org\/10.1007\/s42250-024-01093-z","journal-title":"Chem Afr"},{"key":"680_CR32","doi-asserted-by":"publisher","first-page":"115429","DOI":"10.1016\/j.biopha.2023.115429","volume":"166","author":"CH Hsieh","year":"2023","unstructured":"Hsieh CH, Huang CT, Cheng YS et al (2023) Homoharringtonine as a PHGDH inhibitor: Unraveling metabolic dependencies and developing a potent therapeutic strategy for high-risk neuroblastoma. Biomed Pharmacother 166:115429. https:\/\/doi.org\/10.1016\/j.biopha.2023.115429","journal-title":"Biomed Pharmacother"},{"key":"680_CR33","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1351\/PAC-REC-12-05-10","volume":"85","author":"GR Desiraju","year":"2013","unstructured":"Desiraju GR, Shing Ho P, Kloo L et al (2013) Definition of the halogen bond (IUPAC recommendations 2013). Pure Appl Chem 85:1711\u20131713. https:\/\/doi.org\/10.1351\/PAC-REC-12-05-10","journal-title":"Pure Appl Chem"},{"key":"680_CR34","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1039\/D4RA07467J","volume":"15","author":"J Phetcharawetch","year":"2025","unstructured":"Phetcharawetch J, Uppalabat T, Sawektreeratana N et al (2025) Identification of sulfonylated indolo[1,2-a]quinolines as EGFR tyrosine kinase inhibitors. RSC Adv 15:3139\u20133146. https:\/\/doi.org\/10.1039\/D4RA07467J","journal-title":"RSC Adv"},{"key":"680_CR35","doi-asserted-by":"publisher","first-page":"e1501240","DOI":"10.1126\/sciadv.1501240","volume":"2","author":"D Chen","year":"2016","unstructured":"Chen D, Oezguen N, Urvil P et al (2016) Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv 2:e1501240. https:\/\/doi.org\/10.1126\/sciadv.1501240","journal-title":"Sci Adv"},{"key":"680_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/cmb.2014.0192","volume":"22","author":"DE Chen","year":"2015","unstructured":"Chen DE, Willick DL, Ruckel JB, Floriano WB (2015) Principal component analysis of binding energies for single-point mutants of hT2R16 bound to an agonist correlate with experimental mutant cell response. J Comput Biol 22:37\u201353. https:\/\/doi.org\/10.1089\/cmb.2014.0192","journal-title":"J Comput Biol"},{"key":"680_CR37","doi-asserted-by":"publisher","first-page":"e202404723","DOI":"10.1002\/slct.202404723","volume":"10","author":"YE Maulana","year":"2025","unstructured":"Maulana YE, Danova A, Hermawati E, Alni A (2025) Metal-free electrochemical reduction of nitroquinazoline derivatives towards synthesis of afatinib and dacomitinib. ChemistrySelect 10:e202404723. https:\/\/doi.org\/10.1002\/slct.202404723","journal-title":"ChemistrySelect"},{"key":"680_CR38","unstructured":"Scholl M (2010) Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors. US Patent 20100240649A1"},{"key":"680_CR39","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1016\/j.bmc.2016.04.046","volume":"24","author":"J Shao","year":"2016","unstructured":"Shao J, Chen E, Shu K et al (2016) 6-Oxooxazolidine\u2013quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR. Bioorg Med Chem 24:3359\u20133370. https:\/\/doi.org\/10.1016\/j.bmc.2016.04.046","journal-title":"Bioorg Med Chem"},{"key":"680_CR40","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ejmech.2018.11.029","volume":"162","author":"R Castelli","year":"2019","unstructured":"Castelli R, Bozza N, Cavazzoni A et al (2019) Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR. Eur J Med Chem 162:507\u2013524. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.029","journal-title":"Eur J Med Chem"},{"key":"680_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.saa.2019.04.047","volume":"219","author":"W Wang","year":"2019","unstructured":"Wang W, Gan N, Sun Q et al (2019) Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation. Spectrochim Acta A Mol Biomol Spectrosc 219:83\u201390. https:\/\/doi.org\/10.1016\/j.saa.2019.04.047","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"680_CR42","doi-asserted-by":"publisher","unstructured":"Hermanto FE, Warsito W, Rifa\u2019i M, Widodo N (2023) Understanding hypocholesterolemic activity of soy isoflavones: completing the puzzle through computational simulations. J Biomol Struct Dyn 41:9931\u20139937. https:\/\/doi.org\/10.1080\/07391102.2022.2148752","DOI":"10.1080\/07391102.2022.2148752"},{"key":"680_CR43","doi-asserted-by":"publisher","unstructured":"E Krieger T Darden SB Nabuurs et al 2004Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins: Structure, Function and Genetics 57:678\u2013683. https:\/\/doi.org\/10.1002\/prot.20251","DOI":"10.1002\/prot.20251"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00680-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00680-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T06:38:42Z","timestamp":1764398322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00680-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00680-7","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"102"}}